Key facts
- This page summarizes Eric Swayze's Form 4 filing for IONIS PHARMACEUTICALS INC (IONS).
- 8 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 06 Jan 2026, 17:35.
Eric Swayze - 02 Jan 2026 Form 4 Insider Report for IONIS PHARMACEUTICALS INC (IONS)
- Reporting relationship
- EVP Research
- Issuer ticker
- IONS
- Reported as of
- 02 Jan 2026
- Net transaction value
- -$427,662
- SEC form
- 4
- Accepted by SEC
- 06 Jan 2026, 17:35:26 UTC
- Prior SEC filing
- 16 Oct 2025
- Next SEC filing
- 20 Jan 2026
- Source filing
- View source filing
- Reporting owner signature
- By: Patrick R. O'Neil, attorney-in-fact For: Eric Swayze
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Eric Swayze filed Form 4 for IONIS PHARMACEUTICALS INC (IONS) on 06 Jan 2026.
Change
- Previous filing in this sequence was filed on 16 Oct 2025.
- Current net transaction value: -$427,662.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001791058
Primary reporting owner
Swayze Eric
- Relationship
- EVP Research
- Address
- 2855 GAZELLE COURT, CARLSBAD
- Signature
- By: Patrick R. O'Neil, attorney-in-fact For: Eric Swayze
- Signature date
- 05 Jan 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
IONS
transaction
Common Stock
Options Exercise
- Transaction value
- $312,061
- Shares
- +5,125
- Change %
- +17%
- Price
- $60.89
- Shares after
- 35,578
- Date
- 02 Jan 2026
- Ownership
- Direct
IONS
transaction
Common Stock
Sale
- Transaction value
- $402,671
- Shares
- -5,125
- Change %
- -14%
- Price
- $78.57
- Shares after
- 30,453
- Date
- 02 Jan 2026
- Ownership
- Direct
- Footnotes
- F1, F2
IONS
transaction
Common Stock
Options Exercise
- Transaction value
- $1,116,601
- Shares
- +18,338
- Change %
- +60%
- Price
- $60.89
- Shares after
- 48,791
- Date
- 02 Jan 2026
- Ownership
- Direct
IONS
transaction
Common Stock
Sale
- Transaction value
- $1,453,653
- Shares
- -18,338
- Change %
- -38%
- Price
- $79.27
- Shares after
- 30,453
- Date
- 02 Jan 2026
- Ownership
- Direct
- Footnotes
- F1, F3
IONS
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 256
- Date
- 02 Jan 2026
- Ownership
- by Son
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
IONS
transaction
Derivative
Non-Qualified Stock Option (right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -5,125
- Change %
- -19%
- Price
- $0.000000
- Shares after
- 22,403
- Date
- 02 Jan 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 5,125
- Exercise price
- $60.89
IONS
transaction
Derivative
Non-Qualified Stock Option (right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -18,338
- Change %
- -82%
- Price
- $0.000000
- Shares after
- 4,065
- Date
- 02 Jan 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 18,338
- Exercise price
- $60.89
IONS
transaction
Derivative
Non-Qualified Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +19,350
- Change %
- Price
- $0.000000
- Shares after
- 19,350
- Date
- 02 Jan 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 19,350
- Exercise price
- $79.67
- Footnotes
- F4
IONS
transaction
Derivative
Non-Qualified Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +150
- Change %
- Price
- $0.000000
- Shares after
- 150
- Date
- 02 Jan 2026
- Ownership
- by Son
- Underlying class
- Common Stock
- Underlying amount
- 150
- Exercise price
- $79.67
- Footnotes
- F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 5 footnotes
Footnote F1
Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on August 14, 2024.
Footnote F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.155 to $78.88 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
Footnote F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.88 to $79.70 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.
Footnote F4
Grant on 01/02/2026 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/02/2026. 25% of the shares subject to the option will vest and become exercisable on 01/02/2027. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.
Footnote F5
Grant on 01/02/2026 to reporting person's son of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/02/2026. 25% of the shares subject to the option will vest and become exercisable on 01/02/2027. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.